Medivir AB (MVIRb.F) Release: Primary Efficacy and Safety Findings From Phase III Study of Simeprevir in Treatment-Experienced Patients Demonstrate Sustained Virologic Response
5/21/2013 9:19:22 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen R&D
Ireland (Janssen) today announced primary efficacy and safety results from the
global phase III PROMISE study. Results demonstrated that use of the
investigational protease inhibitor simeprevir (TMC435) led to sustained
virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of
treatment-experienced genotype 1 chronic hepatitis C adult patients with
compensated liver disease, including all stages of liver fibrosis. Simeprevir
was administered once daily with pegylated interferon and ribavirin.
Help employers find you! Check out all the jobs and post your resume.
comments powered by